Almirall receives NICE backing for new psoriasis therapy

Almirall has received backing from the National Institute for Health and Care Excellence (NICE) for its new psoriasis therapy Skilarence.

The drug is intended for patients with moderate to severe plaque psoriasis, which affects approximately 90 per cent of all those diagnosed with the dermatological condition.

Skilarence (dimethyl fumarate) has been recommended for use in patients for whom other non-biological treatments have been deemed unsuitable.

Clinical trials involving the new Almirall therapy found that it helped to clear up severe psoriasis better than placebo treatments, but does not currently go quite as far as Celgene's Otezla in reducing the symptoms of the skin condition, NICE stated.

An appraisal committee for the official healthcare body explained that it is important for people living with psoriasis to have access to a variety of therapies as the condition can be distressing and debilitating.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image credit: Farina2000 via iStock